Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro

被引：19

作者：

Martinez, Luis R. ^{[1
]}

Christaki, Eirini ^{[1
]}

Casadevall, Arturo ^{[1
]}

机构：

[1] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2006年 / 194卷 / 02期

关键词：

D O I：

10.1086/504722

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The fungus Cryptococcus neoformans possesses a polysaccharide capsule and can form biofilms on medical devices. We investigated the efficacy that the combination of a specific antibody to the capsular polysaccharide and antifungal therapy has against cryptococcal biofilms. The antibody enhanced the susceptibility of planktonic cells to antifungal agents, but an antagonistic effect was observed for combination therapy against C. neoformans biofilms. Our findings suggest that antibody therapies for infectious diseases that involve biofilms may antagonize certain antimicrobial therapies, and they also imply that products of the immune response may contribute to drug resistance of biofilms formed in vivo.

引用

页码：261 / 266

页数：6

共 15 条

[1]

Banerjee U, 1997, J MED VET MYCOL, V35, P139

[2] CRYPTOCOCCAL INFECTION OF A PROSTHETIC DIALYSIS FISTULA [J].

BRAUN, DK ;

JANSSEN, DA ;

MARCUS, JR ;

KAUFFMAN, CA .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (05) :864-867

[3]

Casadevall A, 1998, CRYPTOCOCCUS NEOFORM, DOI DOI 10.1128/9781555818241

[4] IMPROVED AMPHOTERICIN-B ACTIVITY BY A MONOCLONAL ANTI-CRYPTOCOCCUS-NEOFORMANS ANTIBODY - STUDY DURING MURINE CRYPTOCOCCOSIS AND MECHANISMS OF ACTION [J].

DROMER, F ;

CHARREIRE, J .

JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (05) :1114-1120

[5] Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis [J].

Larsen, RA ;

Pappas, PG ;

Perfect, J ;

Aberg, JA ;

Casadevall, A ;

Cloud, GA ;

James, R ;

Filler, S ;

Dismukes, WE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :952-958

[6] Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro [J].

Martinez, LR ;

Casadevall, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :1021-1033

[7] Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy [J].

Martinez, LR ;

Casadevall, A .

INFECTION AND IMMUNITY, 2005, 73 (10) :6350-6362

[8] Human recombinant antibody to HSP90: A natural partner in combination therapy [J].

Matthews, RC ;

Burnie, JP .

CURRENT MOLECULAR MEDICINE, 2005, 5 (04) :403-411

[9] Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90 [J].

Matthews, RC ;

Rigg, G ;

Hodgetts, S ;

Carter, T ;

Chapman, C ;

Gregory, C ;

Illidge, C ;

Burnie, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2208-2216

[10] A SIMPLIFIED NEW ASSAY FOR ASSESSMENT OF FUNGAL CELL-DAMAGE WITH THE TETRAZOLIUM DYE, (2,3)-BIS-(2-METHOXY-4-NITRO-5-SULFENYL)-(2H)-TETRAZOLIUM-5-CARBOXANILIDE (XTT) [J].

MESHULAM, T ;

LEVITZ, SM ;

CHRISTIN, L ;

DIAMOND, RD .

JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :1153-1156

← 1 2 →